Methodological considerations in quantification of oncological FDG PET studies
- PMID: 19936745
- PMCID: PMC2886126
- DOI: 10.1007/s00259-009-1306-7
Methodological considerations in quantification of oncological FDG PET studies
Abstract
Purpose: This review aims to provide insight into the factors that influence quantification of glucose metabolism by FDG PET images in oncology as well as their influence on repeated measures studies (i.e. treatment response assessment), offering improved understanding both for clinical practice and research.
Methods: Structural PubMed searches have been performed for the many factors affecting quantification of glucose metabolism by FDG PET. Review articles and references lists have been used to supplement the search findings.
Results: Biological factors such as fasting blood glucose level, FDG uptake period, FDG distribution and clearance, patient motion (breathing) and patient discomfort (stress) all influence quantification. Acquisition parameters should be adjusted to maximize the signal to noise ratio without exposing the patient to a higher than strictly necessary radiation dose. This is especially challenging in pharmacokinetic analysis, where the temporal resolution is of significant importance. The literature is reviewed on the influence of attenuation correction on parameters for glucose metabolism, the effect of motion, metal artefacts and contrast agents on quantification of CT attenuation-corrected images. Reconstruction settings (analytical versus iterative reconstruction, post-reconstruction filtering and image matrix size) all potentially influence quantification due to artefacts, noise levels and lesion size dependency. Many region of interest definitions are available, but increased complexity does not necessarily result in improved performance. Different methods for the quantification of the tissue of interest can introduce systematic and random inaccuracy.
Conclusions: This review provides an up-to-date overview of the many factors that influence quantification of glucose metabolism by FDG PET.
Figures



Similar articles
-
Clinical evaluation of PET image reconstruction using a spatial resolution model.Eur J Radiol. 2013 May;82(5):862-9. doi: 10.1016/j.ejrad.2012.11.015. Epub 2012 Dec 17. Eur J Radiol. 2013. PMID: 23254158
-
Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects.J Nucl Med. 2015 Sep;56(9):1366-71. doi: 10.2967/jnumed.115.154211. Epub 2015 Jul 9. J Nucl Med. 2015. PMID: 26159590
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Standards for PET image acquisition and quantitative data analysis.J Nucl Med. 2009 May;50 Suppl 1:11S-20S. doi: 10.2967/jnumed.108.057182. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380405 Review.
-
A new dimension of FDG-PET interpretation: assessment of tumor biology.Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1158-70. doi: 10.1007/s00259-010-1713-9. Epub 2011 Jan 12. Eur J Nucl Med Mol Imaging. 2011. PMID: 21225422 Review.
Cited by
-
Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network.J Nucl Med. 2019 May;60(5):677-682. doi: 10.2967/jnumed.118.219998. Epub 2018 Dec 7. J Nucl Med. 2019. PMID: 30530829 Free PMC article.
-
A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy.Phys Med Biol. 2017 May 7;62(9):3639-3655. doi: 10.1088/1361-6560/aa6023. Epub 2017 Feb 13. Phys Med Biol. 2017. PMID: 28191877 Free PMC article. Clinical Trial.
-
Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):469-78. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 26550538 Free PMC article.
-
Guidelines for quality control of PET/CT scans in a multicenter clinical study.EJNMMI Phys. 2017 Sep 18;4(1):23. doi: 10.1186/s40658-017-0190-7. EJNMMI Phys. 2017. PMID: 28924696 Free PMC article.
-
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):985-96. doi: 10.1007/s00259-013-2391-1. Epub 2013 Apr 6. Eur J Nucl Med Mol Imaging. 2013. PMID: 23564036 Free PMC article. Clinical Trial.
References
-
- Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508. - PubMed
-
- Avril N, Bense S, Ziegler SI, Dose J, Weber W, Laubenbacher C, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med. 1997;38:1186–1191. - PubMed
-
- Weber WA. 18F-FDG PET in non-Hodgkin’s lymphoma: qualitative or quantitative? J Nucl Med. 2007;48:1580–1582. - PubMed
-
- Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626–1632. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources